NEPH (Nephros) Change In Working Capital : $-2.13 Mil (TTM As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Nephros Change In Working Capital?

Nephros's change in working capital for the quarter that ended in Sep. 2024 was $-0.94 Mil.

Nephros's change in working capital for the fiscal year that ended in Dec. 2023 was $0.83 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Nephros Change In Working Capital Historical Data

The historical data trend for Nephros's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Change In Working Capital Chart

Nephros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-0.89

-3.49

0.88

0.43

0.83

Nephros Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Working Capital	Get a 7-Day Free Trial															0.53	-0.21	-0.72	-0.26	-0.94

Nephros Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.13 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Nephros Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Nephros's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

NPJP:Germany

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Executives

Arthur H Amron	director	C/O WEXFORD CAPITAL LP, 777 WEST PUTNAM AVENUE, FIRST FLOOR, GREENWICH CT 06830
Banks Robert R. Jr.	director, officer: President and CEO	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel	officer: Chief Financial Officer	320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo	officer: Chief Marketing Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor	officer: Chief Financial Officer	380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	director, 10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino	officer: Chief Financial Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans	director, officer: President and CEO	C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079